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Abstract: To investigate the association between serum calcium and risk of breast cancer using a
large cohort and a systematic review with meta-analysis. From the Swedish Apolipoprotein Mortality
Risk (AMORIS) Study we included 229,674 women who had baseline measurements of serum total
calcium and albumin. Multivariable Cox regression was used to assess the association between total
and albumin-corrected calcium and breast cancer risk. For the systematic review, an electronic search
of MEDLINE and EMBASE databases was performed to identify other prospective cohorts assessing
the relationship between serum calcium and breast cancer risk. We pooled the results of our AMORIS
cohort with other eligible studies in a meta-analysis using a random effects model. I2 test was used to
assess heterogeneity. In the AMORIS study, 10,863 women were diagnosed with breast cancer (mean
follow-up: 19 years). We found an inverse association between total serum calcium and breast cancer
when comparing the fourth quartile to the first quartile (HR: 0.94, 95% CI: 0.88–0.99, p value for trend
0.04) and similar results using albumin-corrected calcium. In the systematic review, we identified
another two prospective cohorts evaluating pre-diagnostic serum total calcium and breast cancer.
Combining these studies and our findings in AMORIS in a meta-analysis showed a protective effect
of serum calcium against breast cancer, with a summary RR of 0.80 (95% CI: 0.66–0.97). No substantial
heterogeneity was observed. Our findings in AMORIS and the meta-analysis support an inverse
association between serum calcium and breast cancer risk, which warrants mechanistic investigations.
Keywords: calcium; breast cancer; albumin; prospective study
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1. Introduction
There is ongoing debate surrounding the role of calcium in cancer prevention. In the context
of breast cancer, current findings are mostly focused on dietary calcium with limited evidence on
biomarker levels, denoting an unclear role of the calcium metabolism. For instance, an inverse
association with dietary calcium intake was shown in a meta-analysis including fifteen observational
studies [1], with an approximate 19% reduction in breast cancer risk observed among those in highest
quantile of calcium intake compared to the lowest quantile. This protective effect is thought to be
majorly underlain by chemopreventative actions of 1,25-dihydroxyvitamin D (1,25(OH)2D), the active
form of vitamin D, a well-known regulator of calcium. In experimental studies, 1,25(OH)2D has been
shown to induce differentiation and apoptosis and inhibit cellular proliferation and angiogenesis in
normal and malignant breast cells [2–4]. Similar associations were reported in observational studies,
where a meta-analysis showed that levels of circulating 1,25(OH)2D inversely correlated with risk of
breast cancer [5]. On the other hand, evidence on the role of circulating calcium levels in breast cancer
is limited [6,7].
In addition to 1,25(OH)2D, calcium metabolism is also regulated by other hormonal factors, such
as parathyroid hormone (PTH), which altogether maintain serum ionized calcium, the active form,
within a tight physiological range of approximately 10% [8]. Nevertheless, most observational studies
focusing on the role of calcium in breast cancer utilized dietary calcium rather than its circulating
levels, which may better reflect the extent of calcium homeostasis. In order to elucidate the role of
circulating calcium levels in breast cancer development, we investigated the association between
prediagnostic serum calcium and breast cancer risk in a large prospective cohort study including more
than 220,000 women. Additionally, we systematically reviewed evidence from observational studies
on the association between serum calcium and risk of breast cancer and carried out a meta-analysis for
prospective studies to further clarify any association.
2. Results
2.1. The AMORIS Study
Characteristics of study participants are displayed in Table 1. A total of 10,863 (4.73%) women were
diagnosed with breast cancer during follow-up (mean: 19 years). Mean calcium level was 2.38 mmol/L
(SD: 0.10; range: 1.00 to 3.72) and mean albumin level was 42.50 g/L (SD: 2.74; range: 21 to 57).
The majority (>95%) of the participants had serum calcium and albumin within normal range based on
the laboratory cut-offs. When comparing the lowest and highest quartiles of serum calcium, women
in highest quartiles of total and albumin-corrected calcium had greater age, higher education levels,
and more co-morbidities. In univariable analysis of serum calcium, each covariate showed significant
correlation with serum calcium (Table S1).
When assessing total serum calcium in relation to breast cancer risk, we found that higher calcium
corresponded to a lower risk of breast cancer, with a hazard ratio (HR) for breast cancer of 0.78% and
95% confidence intervals (CI) of 0.63 to 0.97. This inverse trend was also seen when analyzing total
calcium using its quartiles (HR: 0.94 (95% CI: 0.88–0.99) for the fourth compared to the first quartile,
p-value for trend 0.04). Similarly, an inverse association was observed when albumin-corrected calcium
was assessed (HR: 0.93 (95% CI: 0.88–0.99) for the fourth compared to the first quartile, p-value for trend
0.05). When serum albumin was assessed, no association with breast cancer risk was found (HR: 0.99,
95% CI: 0.98–1.01 for every g/L increase in albumin). On the other hand, evaluation of age- and
sex-specific categories of calcium did not show any clear association (Table 2), which may be driven by
a lack of precision. We additionally conducted a sensitivity analysis excluding those with follow-up
time less than two years and similar findings were obtained, e.g., HR: 0.93 (95% CI: 0.88–0.99) for the
fourth quartile of calcium when adjusted for albumin, Ptrend = 0.03. Results did not alter when we
only included participants with calcium levels within normal range (results not shown). Associations
between serum calcium and breast cancer were weaker in pre- and postmenopausal women separately
Int. J. Mol. Sci. 2016, 17, 1487 3 of 12
when analyses were stratified using a cut-off age of 50 years (Table S2). Nevertheless, significantly
lower risks of breast cancer with increasing calcium levels were observed among postmenopausal
women (e.g., HR: 0.89, 95% CI: 0.82–0.97 for the fourth compared to the first quartile of calcium when
adjusted for albumin).
Table 1. Characteristics of study population in AMORIS, overall, and for the lowest and highest serum
calcium quartiles.
Serum Calcium (mmol/L)
All (n = 229,674) Q1 < 2.31 (n = 55,357) Q4 ≥ 2.44 (n = 59,462)
Age (years) Mean (SD) 46.16 (15.19) 44.49 (13.72) 48.82 (16.25)
SES
High 82,555 (35.94) 21,707 (39.21) 18,882 (31.75)
Low 116,202 (50.59) 27,295 (49.31) 31,084 (52.28)
Unclassified 30,917 (13.46) 6355 (11.48) 9496 (15.97)
Education Status
High 56,856 (24.76) 15,649 (28.27) 12,233 (20.57)
Middle 98,268 (42.79) 23,918 (43.21) 24,631 (41.42)
Low 62,456 (27.19) 13,182 (21.81) 18,775 (31.57)
Missing 12,094 (5.27)) 2608 (4.71) 3823 (6.43)
Parity
Yes 155,706 (67.79) 38,594 (69.72) 40,094 (67.43)
No 73,968 (32.21) 16,763 (30.28) 19,368 (32.57)
Breast Cancer
Yes 10,863 (4.73) 2656 (4.80) 2829 (4.76)
No 218,811 (95.27) 52,701 (95.20) 56,633 (95.24)
Calcium (mmol/L) Mean (SD) 2.38 (0.10) 2.26 (0.04) 2.50 (0.06)
Corrected Calcium (mmol/L)
Mean (SD) 2.32 (0.09) 2.23 (0.06) 2.43 (0.08)
Albumin (g/L) Mean (SD) 42.50 (2.74) 41.15 (2.65) 43.76 (2.64)
Charlson Comorbidity Index
0 213,122 (92.79) 51,713 (93.42) 54,205 (91.16)
1 8819 (3.84) 2023 (3.65) 2712 (4.56)
2 5692 (2.48) 1155 (2.09) 1870 (3.14)
3+ 2041 (0.89) 466 (0.84) 675 (1.14)
History of Fractures
Yes 173 (0.08) 45 (0.08) 43 (0.07)
No 229,501 (99.92) 55,313 (99.92) 59,419 (99.93)
Seasonality
Spring 66,166 (28.81) 16,150 (29.17) 17,455 (29.35)
Summer 37,733 (16.43) 8996 (16.25) 10,150 (17.07)
Autumn 68,503 (29.83) 16,620 (30.02 16,924 (28.46)
Winter 57,272 (24.94) 13,591 (24.55) 14,933 (25.11)
Follow-up (years) Mean (SD) 19.40 (5.91) 19.58 (5.75) 18.99 (6.31)
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Table 2. Association between serum total calcium (age-specific and albumin-corrected) and risk
of breast cancer. All models are adjusted for age, education, parity, history of fractures, Charlson
Comorbidity Index, and season at index examination.
N (%)
Hazard Ratio (95% CI)
Breast Cancer No Breast Cancer
Calcium, mmol/L 0.78 (0.63–0.97)
Quartiles of calcium
<2.31 2656 (24.45) 52,701 (24.09) 1.00 (Reference)
2.31–2.36 2416 (22.24) 49,109 (22.44) 0.95 (0.90–1.00)
2.36–2.44 2962 (27.27) 60,368 (27.59) 0.96 (0.91–1.01)
≥2.44 2829 (26.04) 56,633 (25.88) 0.94 (0.88–0.99)
p-value for trend 0.04
Calcium according to age-specific cut-offs
Low 128 (1.18) 2337 (1.07) 1.12 (0.94–1.34)
Normal 10,557 (97.18) 212,101 (96.93) 1.00 (Reference)
High 178 (1.64) 4373 (2.00) 0.94 (0.81-1.09)
p-value for trend 0.78
Albumin-corrected calcium, mmol/L 0.79 (0.63–0.99)
Quartiles of albumin-corrected calcium *
<2.26 2320 (21.36) 49,316 (22.54) 1.00 (Reference)
2.26–2.32 2729 (25.12) 56,756 (25.94) 0.94 (0.89–1.00)
2.32–2.38 2697 (24.83) 53,093 (24.26) 0.96 (0.91–1.01)
≥2.38 3117 (28.69) 59,645 (27.26) 0.93 (0.88–0.99)
p-value for trend 0.05
* Model not adjusted for albumin.
2.2. Systematic Review
Figure 1 displays the flow diagram of the search strategy used to select studies in this systematic
review. We identified 654 potentially relevant articles. After excluding duplicates, titles, and abstracts
were screened for the remaining 539 articles. Among these, we excluded 527 studies that did not satisfy
the eligibility criteria based on information in the title and abstract, and articles published based on
previously published studies. Full text was obtained and screened for 12 articles, and further 10 articles
were excluded with reasons summarized in Table S3 (Supplementary Materials). Two articles that met
the inclusion criteria were included in the qualitative assessment and meta-analysis along with the
results of our AMORIS cohort.
Description of eligible studies identified from literature search is displayed in Table 3. Similar to
the AMORIS study, all included studies were prospective cohorts with serum total calcium assessed
prior to follow-up and any diagnosis of breast cancer. A study performed by Almquist and colleagues
were based in Sweden, and the remaining study was conducted in the U.S. Apart from the AMORIS
study, a lack of association between serum total calcium and breast cancer risk was reported by all
studies, with estimates suggesting weak inverse associations [6,9]. All studies reported associations
between serum calcium and breast cancer risk using serum calcium as categories. Although all
contacted authors responded, they reported that estimates based on serum calcium as a continuous
variable were no longer available. In one study by Sprague and colleagues, all women in the highest
quartile of calcium had clinically high calcium levels [6], further rendering direct estimate summary
between studies inappropriate. Therefore, using reported findings from categories, we performed
categorical regression to estimate the linear relationship between serum calcium and breast cancer risk.
Similar to findings using categories of calcium, inverse associations were suggested but no statistically
significant results were observed (Figure 2).
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Table 3. Description of studies included in the meta-analysis apart from the AMORIS study.
Study Country StudyDesign
Sample
Size
Participant
Characteristics
Follow-up
Duration
Assessment of
Serum Calcium
Findings
Adjustment
Estimates Total Calcium(mmol/L)
Breast Cancer
Risk
Almquist et al.
2007 [9] Sweden Cohort 7847
Mean age
52.3 years
Mean:
17.8 years
Serum total
calcium by
photometry
Relative risk
(RR)
<2.29 Reference Age, educational level, BMI, age at
menarche, use of oral contraception, number
of children, use of hormone-replacement
therapy (HRT), smoking status, marital
status, and alcohol consumption
2.29–2.34 0.99 (0.76–1.28)
2.35–2.40 1.05 (0.81–1.36)
≥2.40 0.89 (0.67–1.19)
Sprague et al.
2010 [6] USA Cohort 2338
Mean age
62.0 years
Mean:
14.3 years
Serum total
calcium by
ion-selective
electrode analyzer
Hazard ratio
(HR)
1.40–2.28 Reference
Age, education, menopausal status, age at
menarche, age at menopause, parity, age at
first birth, alcohol consumption, body mass
index, and postmenopausal hormone use
2.39–2.44 0.70 (0.42–1.17)
2.45–2.52 0.84 (0.51–1.40)
2.53–3.16 0.98 (0.60–1.60)
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2.2.1. Methodological Quality
Quality assessment of the selected studies did not identify possible biases that could compromise
the internal validity of the study leading to misinterpretation of the results. The longest follow-up
duration was a mean of 19.40 years from the AMORIS cohort. Serum calcium was measured with
standard laboratory procedures in all included studies. Each of studies included in our qualitative
and quantitative analysis have described the adjustments made for potential confounding factors.
Adjustments for age at baseline, educational level, and parity were performed in all included studies.
Additionally, the studies identified in the systematic review aside from the AMORIS cohort also
adjusted for additional breast cancer risk factors such as age at menarche and body mass index.
2.2.2. Data Synthesis
A meta-analysis including the four studies reporting the association between serum calcium and
breast cancer risk was performed using random-effects models. As shown in Figure 2, an inverse
association was found, with an overall hazard ratio (HR) of 0.80% and 95% confidence intervals (CI)
of 0.66 to 0.97. When assessing heterogeneity, no indication of heterogeneity was found (I2 = 0%).
A funnel plot assessing the risk of publication bias showed symmetric distribution, indicating a lack of
publication bias (Figure S1). A statistical test of asymmetry was not conducted because of the small
number of included studies.
3. Discussion
In the AMORIS cohort, we found that higher serum total calcium contributed to a lower risk of
breast cancer, particularly among women aged fifty and older. Combining our results in AMORIS
and the additional three studies which satisfied our criteria in a meta-analysis, we found that higher
serum calcium levels corresponded to a lower risk of breast cancer in the three prospective cohorts.
There was no indication of publication bias as shown by the symmetrical funnel plot.
Evidence of a protective effect of calcium against breast cancer mostly rose from observational
studies assessing dietary calcium intake [1]. A randomised control trial showed that calcium plus
vitamin D supplementation did not reduce the overall risk of benign proliferative breast disease,
a precursor to breast cancer, in postmenopausal women [10]. A similar lack of findings was apparent
when looking at calcium plus vitamin D supplementation and the incidence of invasive breast cancer
in postmenopausal women [11]. The beneficial effects of dietary calcium in reducing the risk of
breast cancer as reported from population studies vary with menopausal status [2] and a moderately
stronger association has been observed in premenopausal compared to postmenopausal women [12,13].
In a large prospective cohort study, higher dietary calcium intake corresponded to a lower risk of
breast cancer in postmenopausal women, although confounding by use of calcium supplements in
postmenopausal women taking hormone replacement therapy was evident [14]. Nevertheless, calcium
levels are tightly regulated in the body rather than dependent on nutrient intake [8]. Confirming
the suggested protective effect of calcium against breast cancer, we have now shown that circulating
calcium, which is involved in many cellular processes [15], was inversely correlated to the risk of
developing breast cancer. Such protective effect could be explained by increased cytosolic levels of
calcium following higher serum calcium [8] which may affect multiple cellular processes including cell
cycle and apoptosis, possibly via Ras and β-catenin pathways [16].
To our knowledge, this is the largest population-based study describing pre-diagnostic serum
calcium levels and the risk of breast cancer in women, and the first systematic review describing
this association. Results from our meta-analysis confirmed our findings in AMORIS, with higher
pre-diagnostic serum calcium levels suggested to be associated with a lower risk of breast cancer in
women. The calcium metabolism may be involved in carcinogenesis given its link to vitamin D, which
has been linked to breast cancer cell proliferation [2,4]. However, calcium plays a direct role in cell
apoptosis [17]. In cancer cells, abnormal expression of Ca2+ pumps and channels impairs calcium
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homeostasis promoting tumor growth and migration, overcoming apoptosis [17]. Therefore, ionized
calcium levels may predict breast cancer risk, since total calcium levels also account for the calcium
bound to protein. On the other hand, levels of calcium are also influenced by tumor growth among
breast cancer patients, suggesting potential reverse causation [18]. However, our study and other
studies included in the meta-analysis were based on serum calcium measured in samples collected
prior to any diagnosis of breast cancer.
Existing literature discussing pre-diagnostic serum calcium levels and the risk of breast cancer is
limited. In addition to a role in breast cancer incidence, pre-diagnostic calcium levels have additionally
been reported to be associated with breast cancer mortality. Huss and colleagues [19] reported an
inverse relation between pre-diagnostic levels of serum calcium and breast cancer mortality, with
lower breast cancer-specific mortality in patients with serum calcium levels ≥2.44 mmol/L compared
to those with lower levels of calcium (HR: 0.53, 95% CI: 0.30–0.92). However, this association was no
longer seen in a sensitivity analysis excluding women diagnosed with breast cancer within two years
from the date of baseline blood donation. The association between calcium and breast cancer death
is beyond the scope of the current study. Nevertheless, considering the inverse association observed
between calcium levels and breast cancer, it would be of interest to further explore any clinical role of
serum calcium in breast cancer diagnosis and prognosis.
Our analyses in the AMORIS study were strengthened by the large number of women with
measurements of calcium and albumin conducted in the same clinical facility. The study population in
AMORIS included samples from non-hospitalized women. However, the use of a healthy cohort does
not affect the internal validity of our study. Our study is limited by the lack of information on free
ionized calcium. Nevertheless, albumin-corrected serum calcium is considered a valid assessment of
ionized calcium on a group level [20]. There was also a lack of information regarding lifestyle-related
factors such as BMI and hormonal or reproductive factors apart from parity. To address this, we used
age of fifty years as a cut-off for menopause and co-morbidities as a proxy of lifestyle-related disorders.
Finally, we only used a single measurement of serum calcium rather than repeated measurements.
This may have resulted in attenuation of observed associations.
The meta-analysis performed was strengthened by the quality of individual studies, which used
standard assessments of serum calcium and breast cancer incidence. Additionally, we performed
categorical regression allowing comparison of effects between studies assessing calcium as categories.
A limitation of our meta-analysis was the low quantity of primary evidence available because only four
studies, including our AMORIS study, were included. The primary data used in the meta-analysis was
limited to populations from Sweden and the U.S. Nevertheless, similar to the AMORIS study, this does
not affect the internal validity of individual studies. Although adjustment for potential confounders
varied between included studies and may have affected effect size observed, similar directions of
associations were seen in all studies. To further delineate the association between calcium and breast
cancer, future studies should consider both total calcium levels and ionized calcium levels, which are
metabolically active, as well as taking into account metabolic and endocrine regulators of the calcium
metabolism, which may affect the risk of breast cancer.
4. Methods
4.1. The AMORIS Study
4.1.1. Study Population
The Apolipoprotein Mortality Risk (AMORIS) Study has previously been described [21].
The cohort for this study consists of Swedish men and women recruited from the greater Stockholm
area. Sequential blood sampling was performed for these participants at the Central Automation
Laboratory (CALAB) in Stockholm, Sweden, during 1985–1996, for either routine check-ups or
outpatient referrals. None of the participants were inpatients during the time of sampling [22].
From this cohort we identified 229,674 women aged ≥20 with baseline serum calcium and albumin
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and no previous history of breast cancer for inclusion in our study. The study complied with the
Declaration of Helsinki and was approved by the ethics review board of the Karolinska Institute.
Details of breast cancer diagnosis were acquired from the Swedish National Cancer Register and
the Stockholm Clinical Quality Register of Breast Cancer, which has 97% coverage and is validated
in terms of the records of the National Cancer Register. The International Classification of Diseases
version 7 (ICD-7) was used to identify breast cancer cases (ICD-7: 170). Follow-up time was defined as
the period between baseline measurement and diagnosis of breast cancer, death, emigration, or end of
study (31 December 2011), whichever occurred first.
Total serum calcium was measured using colorimetry (coefficient of variation <2.5%), and albumin
was measured using a bromcresolgreen (BCG) method (coefficient of variation <1.8%) [20]. Levels
of uncorrected calcium were categorized as low, normal, or high in terms of whether they were
lower, equal to or higher than the reference intervals respectively, based on age and sex used by
the CALAB laboratory (Panel 1). Calcium levels lower than 1 mmol/L and higher than 4 mmol/L
were consider outliers based on the laboratory practice and were removed from the study population.
Similar procedures were applied for albumin using a lower cut-off of 20 g/dL and upper cut-off
point of 60 g/dL. In addition to total calcium, albumin-corrected calcium was calculated assuming
normal albumin levels; for each 1 g/L that the albumin concentration was below 40 g/L (normal
concentration), the calcium concentration was increased with 0.02 mmol/L [20]. Similar approach was
performed for albumin concentration above 40 g/L. All methods were fully automated, calibrated and
performed at the same accredited laboratory [21].
We also collected information on baseline age (years), parity (nulliparious, 1+) to account for
reproductive risk factors, and categorized the level of education into low (primary school or less),
moderate (high school) and high (higher education). There was a lack of information on potential
lifestyle-related determinants of serum calcium including body mass index (BMI), smoking, and
alcohol consumption [23] for all participants. Since these lifestyle factors are closely linked to other
diseases such as cardiovascular disease, co-morbidities were assessed as a surrogate by calculating
Charlson co-morbidity index (CCI) from the history of hospitalization. The CCI comprises 17 groups
of diseases, with each disease category (1, 2, 3, and 6) carrying a specific weight. These weights were
summated to generate an overall score of four co-morbidity levels, (0, 1, 2, and 3+) representing a scale
ranging from no co-morbidity to severe co-morbidity. We additionally collected information on history
of fractures from the inpatient register. Season at index examination (spring, summer, autumn, winter)
was included as a proxy for vitamin D, since information on its serum levels was unavailable.
4.1.2. Statistical Analysis
Multivariable Cox regression was used to assess the association between continuous levels and
quartiles of total and albumin-corrected calcium in addition to age- and sex-specific categories of
calcium. A test for trend was conducted by using assignment to categories as an ordinal scale.
Adjustments were made across all models for age, education, parity, history of fractures, CCI,
and season at index examination. The Cox proportional hazards models were also adjusted for
albumin levels as a continuous variable when testing the association between uncorrected total calcium
and breast cancer risk. Sensitivity analyses was conducted by excluding those with follow-up time
less than two years (n = 3427) and only including those with calcium levels within normal range,
i.e., 2.2–2.6 mmol/L (n = 222,128). Findings were stratified by age of 50 years as a proxy of menopause.
Statistical significance was defined at two-sided p-value <0.05. All analyses were conducted with
Statistical Analysis Systems (SAS) release 9.4 (SAS Institute, Cary, NC, USA).
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4.2. Systematic Review
4.2.1. Search Strategies
This review was conducted using guidance from the Cochrane Handbook for Systematic Reviews
of interventions [24] and reported in line with the PRISMA guidelines [25]. An electronic search
was performed to identify all original articles describing serum calcium and the risk of breast cancer.
The search was limited to articles on human subjects and published in English only. MEDLINE
and EMBASE databases were searched from their inception to 20 November 2015. The final search
was performed on 20/11/2015. The following full search strategy was used: [cancer OR neoplasm *]
AND breast AND [serum OR blood] AND calcium AND to “causation-etiology (best balance of
sensitivity and specificity)”. Articles describing levels of serum calcium and the risk of breast cancer
in women retrieved through this search were screened by two investigators and any disagreement
was resolved by consensus. Reference lists of the included articles were hand-searched for potentially
relevant articles.
Studies included were prospective population-based cohort which measured serum calcium levels
at baseline and then reported breast cancer incidence during follow-up. Each included cohort study
had to report either risk estimates (relative risks, odds ratios, or hazard ratios) with 95% confidence
intervals (CI), or provide sufficient data to estimate these. We excluded publications when results
from the same study had been published previously. The eligibility of each study was assessed by two
independent investigators.
4.2.2. Data Extraction
The following information was obtained from eligible studies: study design, population,
risk estimates, and their 95% CIs. We extracted the relative risk for serum calcium as a
continuous variable when available, and contacted study authors to request this data if not already
described. All measurements were transformed into a common measurement unit (mmol/L) to
allow comparability. For studies which only reported relative risk in categories e.g., quartiles, the
covariance-corrected method of Greenland and Longnecker [26] was employed using the dosresmeta
package in R version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria) to obtain linear
dose-response estimates. The assignment of interval scores of serum calcium categories from the
original studies were based on medians or means when available. Category midranges were applied
for the remaining closed-ended categories. For upper open-ended categories with bi as the lower
bound of the ith interval and the intervals indexed by i = 1, . . . , n, interval scores were assigned as
bn + 0.5(bn − bn-1) [27]. Correspondingly, interval scores for the lower open-ended categories were
assigned as b2 − 0.5(b2 − b1).
4.2.3. Methodological Quality
We assessed the methodological quality of included studies using three components which
may influence the strength of association between serum calcium and breast cancer risk: duration
of follow-up, validity of serum calcium measurement, and extent of adjustments made for
potential confounders.
4.2.4. Data Synthesis
Qualitatively, we summarized and tabulated information about study participant characteristics,
serum calcium measurements, length of follow-up, and definition of breast cancer diagnosis as
the outcome. A random effects model using an inverse-variance method was used to obtain the
average effect estimates of breast cancer risk by each unit increment in calcium levels. We evaluated
heterogeneity with the I2 statistic as a measure of the proportion of total variation in estimates
attributable to random error, where any values >50% indicated substantial heterogeneity. Publication
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bias was examined with a funnel plot. Sensitivity analysis was performed for prospective cohort
studies. All quantitative data synthesis was performed in RevMan version 5.3 (Copenhagen, Denmark).
5. Conclusions
In the AMORIS study, higher baseline serum calcium was associated with a lower risk of a
breast cancer diagnosis. The meta-analysis confirmed this inverse association between calcium and
subsequent breast cancer risk in prospective cohort studies. To elucidate pathways linking calcium
and breast carcinogenesis the findings need to be confirmed in mechanistic studies and observational
studies integrating information from dietary supplementation of calcium.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/17/9/1487/s1.
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